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Functionalized micro-capillary ﬁlm for the rapid
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A micro-capillary ﬁlm has been developed that offers the
potential for an at-line analytical tool for rapid aggregate
analysis during biopharmaceutical antibody production. A
non-porous walled micro-capillary ﬁlm (NMCF) with cation
exchange functionality was demonstrated to act as a
chromatography medium that could be operated with high
linear ﬂuid velocities and was highly resistant to blockage by
entrained particulates, including cells. The NMCF containing
19 parallel microcapillaries was prepared using a melt
extrusion process from poly(ethylene-vinyl alcohol)
copolymer (EVOH). The NMCF-EVOH was modiﬁed to have
cation-exchange functionality (NMCF-EVOH-SP) and shown to
differentially bind monomer and aggregated species of IgG
antibody directly from a bioreactor. The use of NMCF-EVOH-
SP to quantify aggregate concentrations in monoclonal
antibody preparations in less than 20 minutes was
demonstrated.
Therapeutic mAbs are ideally suited for the treatment of a
wide variety of diseases due to their high specificity for disease-
related antigens, and over 40 have been approved for clinical
use.1 They can also serve as targeting molecules for the delivery
of drugs and toxins to specific cells.2 However, mAbs are expen-
sive to manufacture, complex to purify and require careful moni-
toring during production to ensure that they are fit for clinical
use. Quality control testing of mAb preparations includes assays
for the levels of product purity, as well as undesirable product
variants such as aggregates.3-6
IgG aggregation can occur throughout the production pro-
cess,7 with reported levels reaching as high as 30% within a biore-
actor.8 Whereas visible aggregates tend to be insoluble and are
easily removed with filtration before downstream purification,9
smaller, soluble aggregates are more difficult to remove. The abil-
ity to measure the accumulation of aggregates, at-line, during fer-
mentation and throughout purification would be beneficial to
bioprocessing. Real-time, or near real-time, at-line aggregation
analysis would represent an important step toward dynamic pro-
cess control strategies could be made.
Several methodologies for aggregate analysis exist. The
industry’s standard method for the measurement of aggregation,
size-exclusion chromatography high performance liquid chroma-
tography (SEC HPLC), requires substantial sample pre-treat-
ment, including both cell removal and purification (e.g., Protein
A affinity chromatography) prior to analysis. SEC HPLC analysis
of multiple samples typically takes several hours to complete, and
can only be regarded as an offline measurement. It is therefore
not an appropriate tool for bioreactor process control.
A possible alternative technology is non-porous walled micro-
capillary film (NMCFs), which is composed of micro-structured
continuous micro-capillaries that can be extruded from a range
of thermoplastic polymers in a low cost, scalable procedure.10,11
The material offers an attractive advantage for in-process parame-
ter control as a non-porous substrate because the film can accom-
modate crude cell-containing samples without pre-treatment.
Film mass transfer resistance is low compared to conventional
adsorbents, such as packed bed resins, and higher liquid superfi-
cial flow rates are achievable with NMCF, producing sharp chro-
matography peaks. Previously, Darton et al.12 demonstrated the
use of NMCF-EVOH-SP as a cation exchange adsorbent capable
of binding and separating cationic proteins (lysozyme, cyto-
chrome C) and the anion-exchange NMCF purification of lenti-
virus in the presence of host cells.13
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IgG antibodies are one of the most charged proteins present in
serum-free bioreactor harvest at neutral pH.14 Based on this dis-
tinctive feature, cation exchange chromatography has been
described in several studies as a low-cost, alternative first capture
step to Protein A affinity chromatography.15-17 We hypothesized
that the cation exchange surface of the NMCF-EVOH-SP should
be able to isolate IgG antibody in the presence of cells and host
cell proteins (HCP).
Here, we demonstrate that a chromatography method based
on cation-exchange NMCF can indeed be used to detect
and quantify aggregated antibody in both purified and unpurified
samples. The ability of the analytical test to discriminate and
quantify aggregates in the presence of complex sample matrices,
including HCP and other cell culture media components was
determined.
The following section describes our experimental results. In
order to establish whether NMCF-EVOH-SP is capable of differ-
entially binding monomeric and aggregated IgG, a Stock B sam-
ple (Fig. 1) containing 10% aggregated and 90% monomeric
IgG was loaded, and then followed by a wash step using buffer
containing 50 mM NaCl and finally an elution step with buffer
containing 250 mM NaCl. The results show that the break-
through and wash peaks combined contain the majority of the
monomeric IgG (85%), whereas the elution peak contains the
majority of aggregated IgG (90%). (Fig. 2A). This demonstrates
that aggregated and monomeric IgG bind differentially to
NMCF-EVOH-SP. In addition, the peak amplitude is higher at
a wavelength of 214 nm compared to 280 nm; therefore, detec-
tion at 214 nm was chosen for subsequent experiments. Different
NaCl concentrations (38.5 – 62.5 mM) were tested to optimize
elution peak area. This was tested with a blend of 2 IgG stocks
used to create a range of aggregate IgG from 0% – 10%.
Figure 2B shows that a linear increase in elution peak area was
obtained with 38.5, 50 and 56 mM NaCl wash buffers, but no
increase in elution peak area was observed when a 62.5 mM
NaCl wash buffer was used. Subsequent experiments used
50 mM as the NaCl concentration for the wash buffer.
The NMCF-EVOH-SP was further tested with increasing
concentrations of Stock B, using only a bind and elute method.
Samples with an aggregate concentration of 0.74 mg/mL had
more aggregate within the breakthrough, exceeding the amount
eluted from NMCF-EVOH-SP (Fig. 3A). Thus, the NMCF-
EVOH-SP can only effectively estimate aggregate concentration
below this level. Increasing the level of aggregate above 10% in
the purified antibody sample resulted in significant levels of
aggregated material in both the unbound and wash fractions
(Fig. 3B). As the aggregate concentration increased above 10%,
too much of the aggregate was lost in the breakthrough and wash
for a reliable estimate of aggregate to be made, thus limiting the
range for reliable aggregate estimation to 10% or lower for the
current 5 m length NMCF-EVOH-SP.
When the Protein A-purified IgG aggregate standards were
diluted with the IgG depleted conditioned fermentation medium
(CM) (unbound fraction from Protein A purification), the
Figure 1. Diagram summarizing the creation of the 3 Stocks A, B and C used to blend IgG samples with varying aggregate and HCP levels employed
within this study.
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elution peak area was found to have a
reduced correlation (R2 value of 0.54)
to the aggregate level (Fig. 3C).
The NMCF-EVOH-SP was directly
attached to a WAVE bioreactor in
order to establish a working model of
at-line analysis (Fig. 4A). On day 6 of
the fermentation, the viable cell density
peaked at 20.3 £ 106 cells/mL with
the antibody titer reaching 2.7 mg/mL
on day 14 (Fig. 4B). The NMCF-
EVOH-SP method was run every
4 hours throughout the culture pro-
cess. During the course of fermenta-
tion, the elution peak area increased
and thus predicted an increase in IgG
aggregate, as determined by the
NMCF-EVOH-SP method (Fig. 4C).
However, by the standard technique of
Protein A purification followed by
SEC HPLC analysis, the aggregate level
appeared to remain relatively constant
(Fig. 4D); this result is discussed
below.
Aggregates are a product variant,
which makes them very difficult to
remove and analyze because they share
similar properties to the desired prod-
uct. As aggregates are formed of several
monomer proteins associated together,
they have a greater net charge.9 Based
on this property, NMCF-EVOH-SP
was optimized to selectively isolate
aggregates and provide a quick assay
for determining the aggregate concen-
tration within a given sample.
During IgG aggregate analysis
with the NMCF-EVOH-SP method,
the majority of aggregate is bound to
the NMCF and only eluted with a
relatively high salt wash (250 mM
NaCl) (Fig. 2A). Based on evalua-
tion of purified and non-purified
samples containing monomeric as
well as aggregated antibody, there is
good correlation between aggregate
level and elution peak area, at least
up to 10% aggregate (Fig. 3B). The
preferential binding of aggregate IgG
over monomer is most likely due to
the higher charge density exhibited
by aggregated IgG molecules.18
The limit of the method to accurately measure aggregate
levels above 10% has been attributed to saturation of the
NMCF-EVOH-SP material. This can be clearly seen as a
sharp increase in the unbound fraction at aggregate levels
above 10% (Fig. 3B). The capacity of NMCF-EVOH-SP
could be increased by using longer lengths of NMCF-
EVOH-SP, although this would also increase the back-pres-
sure, and therefore require a lower flow rate, increasing the
sample processing time beyond the 20 minutes needed for
Figure 2. (A) Binding of IgG monomer and aggregate to NMCF-EVOH-SP. The chromatogram shows
absorbance at 214 and 280 nm as well as [NaCl] against CV for a 100 mL Stock B (10% aggregate) sam-
ple at 1 mg/mL. The breakthrough, wash and elution fractions were analyzed with SEC HPLC to deter-
mine the relative percentage of IgG monomer and aggregate. (B) Elution peak area plotted against
percentage of sample aggregate (0%, 2%, 4%, 6%, 8%, and 10%) at a ﬁxed concentration of 1 mg/mL
IgG antibody. Four wash conditions were tested (38.5 mM, 50 mM, 56 mM, and 62.5 mM NaCl) and
were performed in triplicate. The error bars are the standard error of the mean; 38.5 mM, 50 mM, and
56 mM all have R2 values above 0.9 with a linear regression.
814 Volume 7 Issue 5mAbs
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 C
am
br
idg
e] 
at 
06
:40
 14
 O
cto
be
r 2
01
5 
the 5 m film or by reducing the
amount of material loaded onto the
NMCF-EVOH-SP.
Non-specific interaction of fermen-
tation media components also appeared
to compete with aggregated IgG, caus-
ing a depression in the response when
compared with purified samples
(Fig. 3C). This result could be exacer-
bated by the relatively modest concen-
tration of IgG antibody in the mid-
process samples tested (1 mg/mL),
whereas IgG titers from modern fed-
batch processes seen within industry can
be substantially higher, particularly at
the reactor harvest point where IgG val-
ues as high as 10 mg/mL have been
reported.19
During the course of Chinese
hamster ovary (CHO) cell culture,
the at-line analysis data provided by
the NMCF-EVOH-SP method
revealed fluctuations in IgG aggre-
gate levels between »2% and 5%.
The traditional Protein A / SEC
HPLC method suggested that endog-
enous levels of aggregation remained
relatively constant at around 2%
(Fig. 4D). Theoretically, the differ-
ence in these results can be explained
by the NMCF-EVOH-SP method
measuring total aggregated species
whereas the Protein A / SEC HPLC
method only quantified aggregated
species that bind to Protein A in a
filtered sample.20 Furthermore, it is
possible for aggregate species to form
or disassociate due to the purification
conditions.18 However, without
Figure 3. (A) Mass of aggregate present
within the elution peak (black square) and
breakthrough peak (open circle) against
increasing concentration of aggregate
within a given sample. (B) The estimated
mass of aggregate using the NMCF-EVOH-
SP method from the breakthrough, wash
and elution peak fractions against increas-
ing IgG aggregate percentage (0% to
50%). A linear regression line (R2 D 0.91) is
shown for the elution data from 0% to
10% IgG aggregate. (C) Elution peak area
against IgG samples with increasing per-
centage of aggregated IgG (0%, 2%, 4%,
6%, 8%, and 10%) in the absence (dashed
line) or presence (solid line) of HCP Stock
(Fig. 1). All tested samples had an IgG
concentration of 1 mg/mL.
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Figure 4. For ﬁgure legend, see next page.
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purification of the sample, SEC-HPLC would potentially give
an overestimate of aggregate percentage because some HCP
species have a similar retention time to aggregate proteins.
Future work could incorporate an independent method of IgG
aggregate analysis requiring minimal sample preparation to
test this hypothesis. This could be achieved with analytical
ultra-centrifugation, a method that does not alter the solvent
conditions, nor require pre-treatment of the sample, creating a
substantially lower risk of a non-representative result over SEC
HPLC.21
In conclusion, NMCF-EVOH-SP can be used for the detec-
tion and quantitation of aggregated IgG in an at-line format with
CHO fermentations. The critical advantage of this method is its
ability to rapidly work in the presence of complex feed streams to
generate near real time data without the need for sample pre-
treatment. This capability could be very important to evaluate
the effect of cell culture conditions and modulate parameters to
minimize this common product-related impurity. The technique
could also be used in other cell culture scenarios, such as during
clone selection to screen for clones that produce higher aggre-
gates. We envisage use of this type of at-line product quality test-
ing to support the development of dynamic control strategies of
both (fed-) batch and continuous fermentation strategies. Impor-
tantly, because the main chromatography component is made
from an inexpensive material, NMCFs with different selective
chemistries can be developed as disposable bioprocess technolo-
gies, offering the prospect of a range of quality attributes being
tested at-line using this approach.
Materials and Methods
Materials
Poly(ethylene-vinyl alcohol) copolymer (EVOH) containing
32 mol% of ethylene was supplied by Eval-Europe (Cat. No.
F101B). NaOH (Cat. No. S5881), cyanuric chloride (Cat. No.
C95501), acetone (Cat. No. 34850), Na2HPO4 (Cat. No.
S3264), 3-amino-1-propanesulfonic acid (Cat. No. A76109), 2-
(N-morpholino)ethanesulfonic acid hydrate (Cat. No. M8250),
Tris-HCl (Cat. No. T3253), sodium acetate (Cat. No. S8750),
acetic acid (Cat. No. 695092), PBS tablets (Cat. No. P4417) and
NaCl (Cat. No. S3014) were supplied by Sigma-Aldrich. MabSe-
lect SuRe Protein A (Cat. No. 17-5438-01), Cation exchange
Capto S (Cat. No. 17-5441-03), size exclusion resin HiLoad 16/
600 Superdex 200 pg (Cat. No. 28-9893-35) and 22 liter
WAVE Cellbag (Cat. No. CB0022L10–02) were supplied by
GE Healthcare. Amicon 10 kDa centrifuge concentrators were
supplied by Millipore, (Cat. No. UFC801024A) A MedImmune
proprietary human IgG antibody with molecular weight of
»150 kDa, and an isoelectric point above pH 7.0, produced
from a MedImmune CHO cell clone, was used for all
experiments.
Production of NMCF-EVOH disc
Nineteen-capillary NMCFs were fabricated with a capillary
diameter of 142 mm and a total width of 8 mm by melt extru-
sion of poly(ethylene-vinyl alcohol) copolymer at 200C as
described by Hallmark et al.11 Five meter lengths of NMCF-
EVOH were spirally-wound into discs and the 2 exposed ends
potted into 1/4-inch HPLC connectors (using Upchurch compo-
nents P-652, P-684, U-660X, U-662X and 1652) using slow-set-
ting epoxy-resin (Araldite Rapid).
Surface modification of NMCF-EVOH disc with sulfonic
acid chemistries
The internal surfaces of the microcapillaries in the NMCF-
EVOH disc were functionalized for cation exchange chromatog-
raphy using a procedure adapted from McCreath et al.22 and
detailed in Darton et al.12 Briefly, the 5 m length of NMCF-
EVOH was attached to an HPLC pump and placed in an ice
bath. Thirty mL of ice-cold NaOH (1 M) was first recycled
through the NMCF for 30 min in order to form alkoxide groups
on the vinyl alcohol on the NMCF surface. Then, 20 mL ice-
cold cyanuric chloride (50 mM) in acetone was recycled through
the NMCF in an ice bath for 20 min, followed by a wash with
10 mL ice-cold MilliQ water for 10 min. This was followed by
the addition of the cation exchange group using a 20 mL solu-
tion of 180 mM 3-amino-1-propanesulfonic acid, 100 mM
Na2HPO4, pH 9.1. This solution was recycled at 1 mL/min
through the NMCF-EVOH at 40C for 17 hours. The tempera-
ture was increased to 60C and recycling of the reagent was con-
tinued for a further for 5 hours. Twenty mL of MilliQ water was
then passed through the NMCF for 20 minutes, followed by
20 mL of NaOH (0.4 M) for 20 minutes, and finally a wash
with 20 mL MilliQ water for 20 minutes. The modified
NMCF-EVOH-SP was then stored at 4C in 20 mM Tris-HCl,
pH 7.6.
Preparation of immunoglobulin G aggregate samples
Three stock solutions of aggregated IgG antibody were created
from pre-purified Protein A eluate antibody solutions (Fig. 1).
The antibody was produced using a CHO cell line grown in
Figure 4 (See previous page). (A) Schematic representation of the at-line experimental setup. The WAVE Cellbag as well as the NMCF-EVOH-SP are con-
nected via tubing to the numbered valves of the €ATKA Explorer. The NMCF-EVOH-SP is also connected to the €ATKA’s UV detector for monitoring. Arrows
indicate the direction of liquid ﬂow. Within the valve, the solid lines indicate the ﬂow path in the ‘load’ position, and the dashed lines indicate the ﬂow
path during ‘inject’. (B) Left Y-axis: total cell counts (gray square) and viable cell counts (white diamond) and right Y-axis: IgG titer (black triangle) against
time in the bioreactor post-inoculation. (C) At-line bioreactor monitoring on samples collected every 4 hours using the NMCF-EVOH-SP method showing
the wash peak area (gray square) and elution peak area (black diamond) against time in the bioreactor post-inoculation. A valve failure prevented collec-
tion of samples between days 4 and 7. (D) Aggregate percentage as predicted by at-line NMCF-EVOH-SP (gray square), compared to the standard Protein
A / SEC HPLC method (black diamond) against time in the bioreactor post-inoculation.
www.tandfonline.com 817mAbs
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 C
am
br
idg
e] 
at 
06
:40
 14
 O
cto
be
r 2
01
5 
serum-free medium, both proprietary to MedImmune, in
500 mL cultures with a seeding cell population of 0.3 £ 106 via-
ble cells/mL, agitated at 120 rpm in a humidified incubator at
36.5C and split every 3 to 4 d. Once a sufficient cell density was
achieved, the cultures were clarified by filtration (1.2 mm,
0.45 mm and 0.22 mm membrane filter, PALL) before analysis.
The clarified harvest was loaded onto 20 cm bed height Mab-
Select SuRe Protein A columns, using PBS buffer (pH 7.2) for
equilibration and wash, 50 mM sodium acetate (pH 3) for elu-
tion and 0.1 M acetic acid to recover the column. The eluate was
used for subsequent aggregate stock generation.
The stock solution containing 0% aggregate, herein referred
to as Stock A, was made by purification of the IgG isolated by
Protein A chromatography using a Capto S cation exchange col-
umn, equilibrated and washed with 50 mM sodium acetate
pH 5, and eluted in a gradient of 10 CV up to 300 mM NaCl,
whereupon the eluate contained »0% aggregate.
The second stock solution of high aggregate IgG (~10% aggre-
gate), herein referred to as Stock B, was derived from a culture
grown under nutrient restricted growth conditions (i.e., for
2 weeks without glucose addition to the culture media). This
resulted in an aggregate level of »10% post-Protein A. Stocks A
and B were blended to form a range of aggregate containing sam-
ples (0%–10%).
The third stock (Stock C) was made to replicate the highest
levels of aggregate seen in industry from bispecific antibodies
(>10%).18 This was achieved with SEC (using HiLoad 16/600
Superdex 200 pg) to isolate the aggregate from Stock B, creating
Stock C (»100% aggregate). The column was equilibrated for
1.5 CV, 20 mL sample injection, followed by 3 CV wash with
50 mM sodium acetate pH 6. Stock C was then blended with
Stock A to create a range of aggregate samples ranging between
20% and 50% aggregate.
In order to determine the selectivity of NMCF-EVOH-SP for
the analysis of aggregates in the presence of media components, a
stock was prepared that contained only IgG-depleted CHO con-
ditioned media (Stock HCP, Fig. 1). This was achieved by col-
lecting the flowthrough from a Protein A column (MabSelect
SuRe), which removed the IgG antibody from the culture fluid.
The Protein A flowthrough (containing the host cell proteins and
other cell and media components) was then spiked with the other
stock solutions to a target antibody concentration of 1 mg/mL.
IgG aggregate analysis by SEC HPLC
Aggregate levels were determined by with SEC HPLC using a
TSKgel 3000 SWXL column (7.8 mm £ 30.0 cm, TOSOH Bio-
science, Cat No. 08541) with a SWXL guard column (6.0 mm £
4.0 cm; TOSOH Bioscience, Cat. No. 08543), connected to an
Agilent 1100 HPLC system equipped with a 280 nm UV detec-
tor, running at 1 mL/min. Only an estimated mass could be cal-
culated based upon the SEC HPLC peak area; a mass balance
was not possible due to the loss of antibody during the use of cen-
trifugal concentrators, and the limits upon the sample volume of
SEC HPLC.
IgG aggregate analysis with NMCF-EVOH-SP
To determine the ability of NMCF-EVOH-SP to bind and
elute IgG antibody, samples were injected using a 100 mL injec-
tion loop of an €AKTA Explorer (GE Healthcare). The flow rate
throughout was 2 mL/min, with a total run time of 18 minutes.
The UV absorbance was monitored at both 280 nm and
214 nm. NMCF equilibration was achieved by passing 4 CV,
each of 1.54 mL, of 50 mM MES buffer, pH 5.5. The 100 mL
sample loop was loaded with aggregate-containing sample and
then passed through the NMCF-EVOH-SP, followed by a wash
step to remove unbound protein (4 CV 50 mM MES, pH 5.5).
The wash was conducted by passing MES buffer with salt within
the ranges of 25 to 75 mM NaCl (8 CV). Subsequently, a step
elution to remove any remaining protein using 50 mM MES
buffer containing 250 mM NaCl was applied to the NMCF (4
CV). Fractions were taken throughout the process. Finally the
NMCF-EVOH-SP was re-equilibrated as above. Collected frac-
tions were used only to confirm the presence of aggregate species.
These fractions were first concentrated from 3 mL to 200 mL
using 10 kDa centrifuge concentrators (Millipore, Cat. No.
UFC801024) and then analyzed by SEC HPLC (as described
above).
IgG aggregate analysis at-line with a bioreactor NMCF-
EVOH-SP
NMCF-EVOH-SP capillaries have a diameter of 142 mm,
which is sufficiently large to allow passage of eukaryotic cells
(10–15 mm in diameter). Samples containing cells were directly
loaded from a bioreactor through a check valve into a 100 mL
sample loop attached to an €AKTA Explorer using the B pump on
the system in a custom setup to draw the sample through the
injection valve into the sample loop (Fig. 4A). Drawing the sam-
ple avoids sheer damage to cells that potentially would have
occurred if they had been passed through the pump. The sample
once loaded was then injected onto the NMCF-EVOH-SP
following the method described above.
The bioreactor, a customized 10 L working volume WAVE
Cellbag was inoculated at an initial cell density of 1.3 £ 106 via-
ble cells/mL in the initial 3 L. This was increased to a final vol-
ume of »6 L with four 750 mL nutrient feed additions during
the 14 day production run. Each day cell counts were measured
on an automated cell counter (Vicell, Beckman Coulter) and glu-
cose was measured on a BioProfile FLEX analyzer (NOVA bio-
medical). Alkali and glucose solutions were supplemented into
the culture to maintain pH and glucose respectively. Dissolved
oxygen, temperature and mixing were controlled by the WAVE-
PODTM1 and 20/50EH rocking platform (GE Healthcare).
Cell-free samples were frozen down each day in order to measure
the total IgG titer using a MedImmune proprietary analytical
Protein A method and the aggregate concentration using the
SEC HPLC method as described above.
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